Falcon Point Capital LLC Buys 373 Shares of Tandem Diabetes Care, Inc. (TNDM)
Falcon Point Capital LLC increased its stake in Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by 0.1% during the second quarter, Holdings Channel reports. The institutional investor owned 261,412 shares of the medical device company’s stock after buying an additional 373 shares during the period. Falcon Point Capital LLC’s holdings in Tandem Diabetes Care were worth $209,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently modified their holdings of the company. Wrapmanager Inc. raised its stake in Tandem Diabetes Care by 59.2% in the first quarter. Wrapmanager Inc. now owns 96,405 shares of the medical device company’s stock valued at $116,000 after buying an additional 35,866 shares during the last quarter. Iguana Healthcare Management LLC raised its stake in Tandem Diabetes Care by 33.3% in the first quarter. Iguana Healthcare Management LLC now owns 100,000 shares of the medical device company’s stock valued at $120,000 after buying an additional 25,000 shares during the last quarter. OLD National Bancorp IN raised its stake in Tandem Diabetes Care by 31.0% in the first quarter. OLD National Bancorp IN now owns 119,779 shares of the medical device company’s stock valued at $144,000 after buying an additional 28,320 shares during the last quarter. Monashee Investment Management LLC purchased a new stake in Tandem Diabetes Care during the first quarter valued at approximately $180,000. Finally, Group One Trading L.P. purchased a new stake in Tandem Diabetes Care during the first quarter valued at approximately $185,000. Institutional investors and hedge funds own 45.22% of the company’s stock.
Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) opened at 0.44 on Monday. The firm has a 50-day moving average price of $0.62 and a 200-day moving average price of $1.27. The stock’s market cap is $22.10 million. Tandem Diabetes Care, Inc. has a 12 month low of $0.39 and a 12 month high of $8.81.
Tandem Diabetes Care (NASDAQ:TNDM) last announced its quarterly earnings results on Thursday, July 27th. The medical device company reported ($0.44) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.48) by $0.04. The company had revenue of $21.30 million for the quarter, compared to analyst estimates of $21.74 million. Tandem Diabetes Care had a negative net margin of 110.70% and a negative return on equity of 1,177.11%. Tandem Diabetes Care’s revenue for the quarter was down 7.4% on a year-over-year basis. During the same quarter last year, the business earned ($0.60) EPS. Equities analysts expect that Tandem Diabetes Care, Inc. will post ($1.79) EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This piece was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2017/08/14/falcon-point-capital-llc-buys-373-shares-of-tandem-diabetes-care-inc-tndm.html.
A number of brokerages have issued reports on TNDM. B. Riley reissued a “neutral” rating and issued a $1.50 target price on shares of Tandem Diabetes Care in a research report on Friday, April 28th. Zacks Investment Research lowered Tandem Diabetes Care from a “hold” rating to a “sell” rating in a research report on Wednesday, August 2nd. One analyst has rated the stock with a sell rating, five have given a hold rating and four have assigned a buy rating to the stock. Tandem Diabetes Care currently has an average rating of “Hold” and a consensus price target of $4.71.
Tandem Diabetes Care Company Profile
Tandem Diabetes Care, Inc is a medical device company. The Company is engaged in designing, developing and commercializing products for people with insulin-dependent diabetes. The Company manufactures and sells three insulin pump products, which include t:slim Insulin Delivery System (t:slim), t:flex Insulin Delivery System (t:flex) and t:slim G4 Insulin Delivery System (t:slim G4).
Want to see what other hedge funds are holding TNDM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tandem Diabetes Care, Inc. (NASDAQ:TNDM).
Receive News & Stock Ratings for Tandem Diabetes Care Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care Inc. and related stocks with our FREE daily email newsletter.